

Supplementary Table 5

Factors related to long-term BZD prescription (≥ 8 months) among the new BZD users with as-needed prescription or regular prescription

	As needed (n=18937)			Regular (n=55107)		
	OR	95% CI	p	OR	95% CI	p
Age	1.01	1.00 to 1.02	<0.01	1.02	1.01 to 1.02	<0.001
Sex, male	1.13	0.95 to 1.35	0.17	1.14	1.05 to 1.23	<0.01
Occupational status, employed	0.97	0.81 to 1.17	0.75	0.98	0.90 to 1.06	0.61
Cancer	1.41	1.17 to 1.71	<0.001	1.11	1.00 to 1.22	0.04
Medical specialty, psychiatry	1.18	0.98 to 1.42	0.08	1.96	1.81 to 2.11	<0.001
Psychiatric diagnosis						
None	Ref.					
Mood disorder (F3)	3.00	2.36 to 3.82	<0.001	3.41	3.08 to 3.77	<0.001
Neurotic, stress-related and somatic disorder (F4)	1.53	1.24 to 1.89	<0.001	1.52	1.38 to 1.67	<0.001
Mood and neurotic disorders (F3 and F4)	4.16	3.24 to 5.34	<0.001	3.53	3.16 to 3.95	<0.001
Other disorders	2.13	1.44 to 3.15	<0.001	2.48	2.05 to 2.99	<0.001
Multiple BZDs on first prescriptions ^a	1.45	0.79 to 2.65	0.23	1.37	1.25 to 1.51	<0.001
Type of BZD ^a						
Hypnotic	Ref.					
Anxiolytic	0.44	0.37 to 0.52	<0.001	0.67	0.62 to 0.72	<0.001
Both	0.70	0.36 to 1.39	0.31	0.99	0.88 to 1.12	0.90
Half-life of BZD ^a						
Short (< 12 h)	Ref.					
Medium (12-24 h)	1.11	0.92 to 1.33	0.28	1.10	1.02 to 1.19	0.02
Long (≥ 24 h)	0.80	0.60 to 1.07	0.13	0.95	0.87 to 1.03	0.22

BZD, benzodiazepines and Z-drugs; OR, odds ratio; CI, confidence interval

a: Characteristics of BZD with the longest prescription days in the first prescription